Skip to main content

Biomedical Research in Melanoma

16
Publications
93.75
%Q1
32
Number of citations
57.14
% Open Access Publications
4
Ongoing Projects
1
Number of Presented Theses
9
Number of Active Clinical Trials
Our group is dedicated to addressing clinically relevant questions related to melanoma and other skin conditions. Over the past year, we have uncovered key interactions between tumor suppressors and melanoma driver genes involved in melanocyte transformation and malignancy. These findings have led to the identification of molecules capable of overriding evolutionary tumor suppressor mechanisms. Additionally, we have contributed to the clinical management of mucosal melanomas and shed light on their prognostic implications and the successful management of patients treated with immunotherapy.

eCORE

  • Cancer

Team

Group Leader
Juan Angel Recio Conde, Vicente García-Patos Briones

Researchers
Kimberley MacGrail

PhD Students
Paula Granado Martínez, Roberto Orsenigo, Carlos González Cruz, Yuxin Ding, Berta Ferrer

Selected Publications

Clavero-Rovira L, Gómez-Tomás Á, Bassas-Freixas P, Bodet D, Ferrer B, Hernández-Losa J, Muñoz-Couselo E, Pérez-Benavente A, García-Patos V, Ferrándiz-Pulido C
Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study.
Cancers (Basel)
DOI: 10.3390/cancers16010227.
IF: 4.55

McGrail K, González-Sánchez E, Granado-Martínez P, Orsenigo R, Ding Y, Ferrer B, Hernández-Losa J, Ortega I, Martín-Caballero J, Muñoz-Couselo E, García-Patos V, Recio JA
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation.
Mol Oncol. 2025 Feb;19(2):329-343.Epub 2024 Aug 8.
DOI: 10.1002/1878-0261.13715
IF: 6.6

González-Cruz C, Muñoz-Couselo E, Ortiz-Velez C, Ferrer B, García-Patos V, Ferrándiz-Pulido C.
Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy.
JAAD . 2024 Mar 1;46:67-69.
DOI: 10.1016/j.jdcr.2024.02.011
IF: 11.5

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA.Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Eur J Cancer. 2024 Mar;199:113542
DOI: 10.1016/j.ejca.2024.113542
IF: 7.6

Selected Projects

p38αtumor-dependent immune evasive mechanisms in melanoma
Principal Investigator: Juan A. Recio
Agency: Instituto de Salud Carlos III
Funding: 321,250 €
Period: 01/01/2024 - 01/01/2027

Development of TET2 activating drugs for the treatment of melanoma
Principal Investigator: Juan A. Recio, Isabel Puig; Hector García Palmer
Agency: Ministerio de Economía y competitividad
Funding: 723,392.47 €
Period: 15/11/2023 - 15/11/2026

Molecular mechanisms in melanomaJuan A. Recio Conde
Principal Investigator: Juan Angel Recio Conde
Agency: Generalitat de Catalunya
Funding: 60,000 €
Period: 31/01/2021 - 31/01/2025

VHIR Annual Report 2024